Cargando…
FDA Modernization Act 2.0: transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches
Autores principales: | Zushin, Peter-James H., Mukherjee, Souhrid, Wu, Joseph C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617761/ https://www.ncbi.nlm.nih.gov/pubmed/37909337 http://dx.doi.org/10.1172/JCI175824 |
Ejemplares similares
-
CellML 2.0
por: Clerx, Michael, et al.
Publicado: (2020) -
Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years
por: Olliaro, Piero L., et al.
Publicado: (2018) -
The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives
por: Niazi, Sarfaraz K
Publicado: (2023) -
mHealth 2.0: Experiences, Possibilities, and Perspectives
por: Becker, Stefan, et al.
Publicado: (2014) -
Beyond sightseeing: How can tourism affect public/global health in modern society?
por: Wen, Jun, et al.
Publicado: (2022)